Nvidia Just Confirmed an Emerging AI Boom in Biotech

1
Comment
Favorite

Nvidia Just Confirmed an Emerging AI Boom in Biotech

InvestorPlace2023-08-07

Trillion-dollar AI chipmaker Nvidia recently announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2357588012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-07 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2357588012","market":"us","top_or_hot":-1,"title":"Nvidia Just Confirmed an Emerging AI Boom in Biotech","media":"InvestorPlace","content":"<div>\n<p>Trillion-dollar AI chipmaker Nvidia recently announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2023/08/ai-meets-biotech-transforming-the-drug-development-process/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia Just Confirmed an Emerging AI Boom in Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia Just Confirmed an Emerging AI Boom in Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-07 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2023/08/ai-meets-biotech-transforming-the-drug-development-process/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Trillion-dollar AI chipmaker Nvidia recently announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2023/08/ai-meets-biotech-transforming-the-drug-development-process/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4503","symbol_name":"景林资产持仓","start_time":0,"source_url":"https://investorplace.com/hypergrowthinvesting/2023/08/ai-meets-biotech-transforming-the-drug-development-process/","article_id":"2357588012","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2357588012","pubTimestamp":1691418943,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"It takes about $900 million and 13.5 years to develop a new successful drug; but not for long. AI is turning that entire process on its head.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4503":"景林资产持仓","AAPL":"苹果","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","LU0056508442.USD":"贝莱德世界科技基金A2","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1829250122.USD":"高盛欧洲核心股票组合Acc","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0238689110.USD":"贝莱德环球动力股票基金","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0072462426.USD":"贝莱德全球配置 A2","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","BK4529":"IDC概念","AZN":"阿斯利康","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU0080751232.USD":"富达环球多元动力基金A","RXRX":"Recursion Pharmaceuticals, Inc.","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0308772762.SGD":"Blackrock Global Allocation A2 SGD-H","BK4568":"美国抗疫概念","NVDA":"英伟达","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4507":"流媒体概念","AMZN":"亚马逊","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","BK4139":"生物科技","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","BK4566":"资本集团","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","SNY":"赛诺菲安万特","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","BK4524":"宅经济概念","BK4501":"段永平概念","BK4527":"明星科技股","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","BK4141":"半导体产品"},"translate_title":"英伟达刚刚证实了生物技术领域新兴的人工智能热潮","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMZN":1,"SNY":1,"RXRX":1,"NVDA":1,"AAPL":1,"AZN":1},"content_text":"Trillion-dollar AI chipmaker Nvidia recently announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone. \n\n\n\n \n\nSource: shutterstock.com/cono0430\n\n\n\nEditor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in July 2023. It has since been updated to include the most relevant information available.\nWe’ve long said that artificial intelligence (AI) will have the most profound economic impact in the medical industry, where it can be used to accelerate and cheapen everything from drug discovery to patient treatment.\nAnd Nvidia (NVDA), the world’s preeminent AI company, may have just confirmed that sentiment last month.\nThe trillion-dollar AI chipmaker announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals (RXRX), which has developed a novel AI-driven platform for drug development and discovery.\nRecursion will train its AI models on Nvidia’s cloud platform, which Nvidia will then license through its newly announced BioNeMo generative AI cloud service for drug discovery.\nNvidia will also pour $50 million into Recursion in exchange for a ~4% stake in the company.\nThis is a massive deal. Look no further than how much RXRX stock rallied before and after the deal was announced.\n\nBut this is likely just the start of the big boom at the convergence of AI and medicine. \nNvidia is a trillion-dollar juggernaut in the world of AI. It could’ve chosen any industry to commit its money and resources to. And of all industries, it chose biotechnology.\nWhy?\nData.\n\n\n\n\n\n\nIn a World of Data, Today’s AI Is Just the Beginning\nLike computers, humans are nothing more than a bunch of data strung together. \nAt their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Human DNA is much the same. We’re just a bunch of As, Gs, Cs, and Ts strung together. Those are the four base types found in human DNA molecules, each determining a person’s characteristics, traits, and even actions. \n\nEssentially, the connecting element here is data. \nThat means AI can have an especially profound impact on the human body. \nAfter all, at the end of the day, what is AI? It is just a machine learning algorithm processing tons of data to learn how to perform a certain task or variety of tasks. It’s all just algorithms and data, with data acting as the model’s “fuel.”\nThe quantity and quality of data an AI model has access to determines the quality of the model itself. \nWhen it comes to the human body, there is no dearth of quality data. As mentioned above, we are nothing more than a bunch of quality genetic data strung together.\nApply AI to all that data, and you will change the world. \nSeriously. \nConsider the value proposition of Recursion’s core AI technology.\nCurrently, it takes about $900 million and 13.5 years to develop a new successful drug. With AI constantly running simulations, drug development could happen in months and for less than $100 million.\nThat may sound hard to believe, but it’s true. Drugs are already being discovered by AI that quickly. \nAI Meets Biotech\nEarlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using artificial intelligence. \nAnd it isn’t alone. \nOther pharma giants like Bayer (BAYRY), Roche (RHHBY), Sanofi (SNY), and AstraZeneca (AZN) are actively using AI technology for drug discovery purposes. \nThe future of drug discovery starts now. \nThis is big business. \nResearch firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. Morgan Stanley believes that AI-powered drug discovery will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!\nSource: Deep Pharma Intelligence\nIn other words, a $50 billion drug discovery revolution starts now. \nIs your portfolio positioned for it?\n\n\n\n\n\n\nThe Final Word\nIf not, I want to tell you about one of my favorite investments for this new bull market. \nOne great prospective investment is the very company that started this whole stock boom – OpenAI, the creator of ChatGPT. \nSince ChatGPT’s launch in November 2022, the company’s valuation has doubled!\nBut that’s just the start. \nI truly believe OpenAI could be one of the world’s largest companies in the near future – if not the largest. \nOpenAI represents the potential investment opportunity of a lifetime. \nToo bad it is a startup that you can’t buy on a public exchange like a big stock… \nThough I did manage to unearth an investment ‘loophole’ that allows you to take a stake in OpenAI now – before its highly anticipated IPO. \nThis is your chance to invest in the next big thing. Like investing in Apple (AAPL) in the 1980s or Amazon (AMZN) in the 1990s, this is an opportunity you can’t afford to miss. \nLearn all about it.\nOn the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/hypergrowthinvesting/2023/08/ai-meets-biotech-transforming-the-drug-development-process/.\n©2023 InvestorPlace Media, LLC","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}